Phase II, randomized, double-blind, placebo-controlled, cross-dose-range study to evaluate the efficacy and safety of INCB054707 in participants with hidradenitis suppurativa
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Developer: INCYTE CORPORATION
- Phase: II
- Execution start: 19/02/2021
- End of execution: 30/09/2022
- IP: ALEJANDRO MOLINA LEYVA